New York, NYNCT07285694Now EnrollingIRB Ready

Metastatic Castration Resistant Prostate Cancer (mCRPC) Clinical Trial in New York, NY

Access cutting-edge metastatic castration resistant prostate cancer (mcrpc) treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Arsenal Biosciences, Inc.

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access metastatic castration resistant prostate cancer (mcrpc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic castration resistant prostate cancer (mcrpc) treatment provided free

Apply for This New York Location

Check if you qualify for this metastatic castration resistant prostate cancer (mcrpc) clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Metastatic Castration Resistant Prostate Cancer (mCRPC) Study in New York

This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).

Sponsor: Arsenal Biosciences, Inc.

Who Can Participate

Inclusion Criteria

At least 18 years of age at time of signing informed consent form.
Histologically confirmed adenocarcinoma of the prostate, meeting all of the following criteria: • Documented progressive metastatic castration-resistant prostate cancer (mCRPC) based on PCWG3 criteria.
Prior prostate cancer treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy. • PSMA+ by PSMA PET.
Measurable disease by RECIST 1.1 criteria, or evaluable disease via measurable PSA (≥ 1 ng/mL) per PCWG3 criteria.
Adequate organ functions. Key

Exclusion Criteria

Any prior systemic therapy for CRPC within 14 days prior to scheduled protocol required leukapheresis.
Central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression.
Unwillingness to participate in an extended safety monitoring period.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07285694) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Castration Resistant Prostate Cancer (mCRPC) Treatment Options in New York, NY

If you're searching for metastatic castration resistant prostate cancer (mcrpc) treatment options in New York, NY, this clinical trial (NCT07285694) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic castration resistant prostate cancer (mcrpc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic castration resistant prostate cancer (mcrpc) clinical trials near you to find additional studies recruiting in your area.

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY